Evercore ISI raised the firm’s price target on 89bio (ETNB) to $37 from $29 and keeps an Outperform rating on the shares. Data for Akero Therapeutics’ (AKRO) efruxifermin showing deep fibrosis responses at 96 weeks bodes well for 89bio’s pegozafermin given that they share a mechanism of action, says the analyst, who is making similar changes to the firm’s 89bio model as it did for Akero following the report of the data.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ETNB:
- 89bio to Participate in the Leerink Partners Global Biopharma Conference
- Akero 96-week update ‘posiitve’ for 89Bio, says Raymond James
- 89Bio Inc Is Worried About This – Should You Be Worried Too?
- 89bio price target lowered to $31 from $32 at H.C. Wainwright
- 89bio reports Q4 EPS (50c), consensus (49c)
